Browse the evidence

Limiting dietary fat and saturated fatty acids is an advised strategy for managing familial hypercholesterolemia.

Practitioners should advise FH patients to limit dietary fat and saturated fatty acids.

Supplementation of phytosterols and fiber can be helpful in managing familial hypercholesterolemia.

Practitioners may consider recommending phytosterol and fiber supplements to FH patients.

Carbohydrate-restricted diets (CRDs) significantly improved glycemic control, including glucose (SMD = -2.94 mg/dL), insulin (SMD = -8.19 pmol/L), and HOMA-IR (-0.54).

Practitioners may consider CRDs as an effective strategy for improving glycemic control in adults.

LCDs and MCDs showed the most consistent metabolic benefits, particularly with combined fat and protein replacements.

Practitioners should consider LCDs and MCDs with mixed macronutrient replacements for optimal metabolic health.

Resistance training at both longer and shorter mean muscle lengths produces similar hypertrophic effects.

Practitioners can use a variety of muscle lengths in resistance training without significantly affecting hypertrophy outcomes.

Higher weekly set volumes produced a detectable advantage for muscle hypertrophy (1.8 cm²) but not maximal strength (3.48 kg).

Practitioners should consider higher training volumes for promoting muscle growth.

Patients on dialysis achieved a mean total body weight loss of 7.8% (SD 6.1) after being prescribed semaglutide.

Semaglutide may be an effective weight loss intervention for patients on dialysis.

48.2% of patients who were ineligible for transplant due to elevated body mass index achieved waitlist activation after successful weight loss.

Successful weight loss with semaglutide can enhance transplant eligibility for patients.

GLP-1RAs promote weight loss and improve metabolic health.

GLP-1RAs can be utilized to aid in weight management and metabolic health improvement.

Phase 2 trials of retatrutide report unprecedented weight reductions comparable to bariatric surgery.

Retatrutide may provide an effective alternative to surgical weight loss methods.

Weight loss was consistently larger in the incretin intervention groups than in placebo or lifestyle intervention comparators.

Incretin therapies may be more effective for weight loss compared to lifestyle changes or placebo.

Semaglutide initiated 6 months post LSG results in significantly greater absolute weight loss of 14.03 ± 5.26 kg compared to 5.63 ± 6.25 kg in controls from 6 to 12 months post LSG (p < 0.0001).

Practitioners may consider semaglutide as an effective adjunct therapy for weight management in patients post-sleeve gastrectomy.

Semaglutide therapy leads to a higher percentage weight loss of 12.61% ± 4.11% compared to 4.84% ± 5.18% in controls from 6 to 12 months post LSG (p < 0.0001).

Semaglutide may be recommended for patients post-surgery to enhance weight loss outcomes.

At 12 months, total weight loss was higher in the treatment group (35.77% ± 8.35%) compared to controls (28.37% ± 7.41%; p < 0.0001).

The findings support the use of semaglutide for improved long-term weight management post-surgery.

Patients with a longer duration of GLP-1RA treatment are more likely to achieve successful weight reduction at follow-up of 12 months (OR = 1.014).

Practitioners should consider the duration of GLP-1RA treatment as a factor in achieving weight loss.

Using semaglutide is associated with successful weight reduction at the follow-up of 6 months (OR = 2.138).

Semaglutide may be a more effective option for weight reduction in patients treated with GLP-1RA.

Weight loss significantly explained heterogeneity in treatment effects on fibrosis improvement and MASH resolution.

Weight management should be emphasized in treatment plans for MASH to enhance treatment efficacy.

GLP-1 receptor agonist treatment is associated with a 10.3% reduction in fat mass (FM) at 6 months, 17.3% at 12 months, and 18.0% at 24 months.

GLP-1RA treatment leads to significant fat mass reduction over 24 months.

GLP-1 receptor agonists produced greater weight loss among women (10.9%; 95% CI, 7.0%-14.8%) than men (6.8%; 95% CI, 4.6%-9.0%).

Practitioners should consider gender differences when prescribing GLP-1 receptor agonists for weight loss.

GLP-1-based medications can achieve up to 24% weight loss, aiding in the effective management of obesity and its complications.

Practitioners can consider GLP-1 medications as a viable option for weight management in obese patients.

Semaglutide, a GLP-1 receptor agonist, can lead to weight reductions of up to 15%.

Practitioners should consider the potential effectiveness of semaglutide for weight loss in patients.

Incretin-based therapies induced substantial weight loss, mostly from fat mass.

Practitioners can consider incretin-based therapies as effective options for promoting fat loss in T2D patients.

Broad access to semaglutide would result in 38,950 cardiovascular events avoided and 6,180 deaths avoided over a 10-year period.

Practitioners should consider the significant health benefits of prescribing semaglutide to eligible Medicare patients.

CagriSema is being marketed as a safe and potentially superior medication to lower both Hemoglobin A1c and body weight.

Practitioners may consider CagriSema as a treatment option for patients needing glycemic control and weight management.